

<b>Appendix Table 1: Changes in Outpatient and Pharmacy Utilization Associated with EMR-Based Clinical Decision Support: Pre, Post, and Difference Estimates</b>				
Intervention				
	Pre	Post	Difference	P-Value
Visits	8.8	9.3	.4	.363
Labs	2.1	2.6	.5	<.001
Pharmacy Fills	36.2	37.0	.8	.853
Control				
	Pre	Post	Difference	P-Value
Visits	10.1	10.7	.6	.243
Labs	2.2	2.6	.4	<.001
Pharmacy Fills	36.3	37.3	1.0	.647
Differences				
	Intervention	Control	DID	P-Value
Visits	.4	.6	-.2	.859
Labs	.5	.4	.1	.389
Pharmacy Fills	.8	1.0	-.2	.949

Estimates are calculated using generalized linear models controlling for age and gender and are standardized to the underlying population characteristics.

<b>Appendix Table 2: Changes in Pharmacotherapy Associated with EMR-Based Clinical Decision Support: Difference-in-Difference Estimates</b>				
	Use of Pharmacotherapy		High Dose Pharmacotherapy	
	Odds Ratio	P-Value	Odds Ratio	P-Value
Insulin	.94	.760	-	-
Sulfonylureas	1.28	.176	1.38	.008
Metformin	.96	.814	.92	.457
Thiazolidinediones	1.56	.059	.64	.040
Exenatide	.40	.052	-	-

This table presents coefficient estimates (displayed as odds ratios) associated with the probability of use of each of the specific types of pharmacotherapy, as well as the probability of filling a prescription for a high vs. low dose (proxied by pill size) among users of each pharmacotherapy. The coefficients estimates are calculated using logistic regression models controlling for age and gender. These are coefficients on the time by study arm interaction term, and thus represent the incremental effect of the intervention on patterns of pharmacotherapy. Use of high dose pharmacotherapy cannot be calculated for intravenous medications including insulin and Exenatide.